SCHEMBL4515136

SCHEMBL4515136

Cc1ccc(S(=O)(=O)N2CCNC(=O)CC2CC(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
POLB P06746 2/20 0.54
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MMP2 P08253 1/20 0.42
ANPEP P15144 1/20 0.42
GFER P55789 1/20 0.42
GAA P10253 3/20 0.41
TSHR P16473 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.40
KDM4E B2RXH2 1/20 0.40
BDKRB1 P46663 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530216 0.87 ALDH1A1 (0.70) ALDH1A1POLBMAPTKMT2ANPSR1
SCHEMBL3534971 0.81 ALDH1A1 (0.76) ALDH1A1POLBMAPTKMT2AGAA
SCHEMBL3534966 0.81 ALDH1A1 (0.76) ALDH1A1POLBMAPTKMT2AGAA
SCHEMBL11113764 0.80 NPSR1 (0.50) ALDH1A1POLBMAPTKMT2ANPSR1
SCHEMBL4507851 0.79 BDKRB1 (0.51) ALDH1A1POLBMAPTKMT2ANPSR1
SCHEMBL7968454 0.78 RAB9A (0.53) GAAHPGD
SCHEMBL7968450 0.78 RAB9A (0.53) GAAHPGD
SCHEMBL7978066 0.78 RAB9A (0.53) GAAHPGD
SCHEMBL5984080 0.73 ALDH1A1 (0.74) ALDH1A1POLBMAPTKMT2AGAA
SCHEMBL5982477 0.73 ALDH1A1 (0.74) ALDH1A1POLBMAPTKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054460-A1 Piperazine derivatives and methods of use CHEN JIAN J 2009-02-26 US disclosed
US-7393852-B2 Piperazine derivatives and methods of use AMGEN INC. (US) 2008-07-01 US disclosed
EP-1656355-B1 PIPERAZINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2008-03-12 EP disclosed
EP-1878728-A2 Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders Amgen Inc. (US) 2008-01-16 EP disclosed
EP-1656355-A2 PIPERAZINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-05-17 EP disclosed
WO-2005061467-A2 PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS AMGEN INC. (US) 2005-07-07 WO disclosed
US-20050014749-A1 analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects AMGEN INC. 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054460-A1 Piperazine derivatives and methods of use PTGES, PTGES2, PTGIS ALDH1A1 184/4885POLB 1384/4885MAPT 3351/4885
US-20050014749-A1 analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects ACHE, TNF, BCHE ALDH1A1 81/4885POLB 3504/4885MAPT 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.